Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Cetuximab for NSCLC, from ASCO 2008

2009 ASCO Annual Meeting

29 May - 2 Jun 2009

Published: 27 Nov 2008

Views: 14855

Rating:

Save

Professor Robert Pirker

Categories:
Lung & pleura

Related Videos

WCI's role in the prevention of tobacco related cancer among Beedi rolling...

Dr Surendran Veeraiah - Cancer Institute (WIA) Adyar, Chennai, India

WCI's role in the prevention of tobacco related cancer among Beedi rolling women in India ( Dr Surendran Veeraiah - Cancer Institute (WIA) Adyar, Chennai, India )

Alternative livelihood training programme for rural women who are employed in...

Ms Sheeba Paul - Exodus Exports Pvt Ltd, Chennai, India

Alternative livelihood training programme for rural women who are employed in the tobacco industry in India ( Ms Sheeba Paul - Exodus Exports Pvt Ltd, Chennai, India )

ESMO and WCLC: Latest developments in EGFR mutated NSCLC

Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale...

ESMO and WCLC: Latest developments in EGFR mutated NSCLC ( Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini )

Predicting tumour mutations from pathology images may help increase...

Dr Rom Leidner - Providence Cancer Institute, Portland, USA

Predicting tumour mutations from pathology images may help increase personalised medicine utilisation ( Dr Rom Leidner - Providence Cancer Institute, Portland, USA )

New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy...

Dr Li Zhang - Sun Yat-Sen University Cancer Centre, Guangzhou, China

New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients ( Dr Li Zhang - Sun Yat-Sen University Cancer Centre, Guangzhou, China )

Tusamitamab ravtansine versus docetaxel in previously treated advanced...

Prof Benjamin Besse - Gustave Roussy, Paris, France

Tusamitamab ravtansine versus docetaxel in previously treated advanced nonsquamous NSCLC: Results from phase 3 CARMEN-LC03 trial ( Prof Benjamin Besse - Gustave Roussy, Paris, France )

Cemiplimab monotherapy could be a new treatment option for first line advanced...

Dr Ana Baramidze - Todua Clinic, Tbilisi, Georgia

Cemiplimab monotherapy could be a new treatment option for first line advanced NSCLC patients ( Dr Ana Baramidze - Todua Clinic, Tbilisi, Georgia )

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC

Dr Marina Garassino - University of Chicago, Chicago, USA

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )

Amivantamab-lazertinib continue to show benefit as a first-line standard-of...

Dr Marina Garassino - University of Chicago, Chicago, USA

Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )

More from ecancer